Abecma, BCMA
Understanding BCMA: A Revolutionary Target in Cancer Treatment
Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted repercussions. One such intri..
Abecma, Breyanzi, CARVYKTI, Kymriah, Tecartus, Yeskarta
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approaches, but Chimeric Antigen Rece..
Abecma, idecabtagene vicleucel, KarMMa-3
CAR T-cell treatment provides significant remission rates in clinical trials
Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple myeloma. Abecma (idecabtagene vicleucel) chimeric antigen receptor ..
Abecma, B-cell maturation antigen, chimeric antigen receptor, idecabtagene vicleucel, proteasome inhibitor, refractory multiple myeloma
The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma
August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therap..